Table 1.
Essential criteria | Additional information | |
---|---|---|
Astrocytoma, IDH‐mutant |
Diffusely infiltrating glioma AND IDH‐mutation AND ATRX mutation OR exclusion of whole arm deletions of 1p and 19q |
ATRX mutation can be demonstrated as loss of nuclear ATRX expression on immunohistochemistry or ATRX mutation on molecular testing. |
Oligodendroglioma, IDH‐mutant 1p/19q‐codeleted |
Diffusely infiltrating glioma AND IDH‐mutation AND Whole arm deletions of 1p and 19q |
Recommended that 1p/19q assays be able to detect whole‐arm chromosomal losses, such as FISH or molecular genetic testing. |
Glioblastoma, IDH‐wildtype |
Diffuse astrocytic glioma AND IDH‐wildtype AND H3‐wildtype |
Must additionally demonstrate one or more of: microvascular proliferation, necrosis, TERT promoter mutation, EGFR gene amplification, chromosome +7/−10 copy number alterations. |
This table summarises the diagnostic criteria for the neuropathological diagnosis of adult‐type diffuse gliomas according to WHO CNS fifth edition [9]. Once a diffusely infiltrating glioma has been identified on histopathology, these criteria must be demonstrated either by immunohistochemistry or DNA sequencing. Alternatively, DNA methylation profiling can also be used. WHO CNS5 also recommends that grade is designated in Arabic numerals, rather than Roman numerals, as in previous editions.